Friday, 16 October 2026European Markets

CHAUSSERIA Stock Over 33% Up In The Last 21 Sessions

Loading stream...

chausseria, a renowned producer of women's footwear under its namesake and janie philip brands, has recently seen a significant upswing in stock market performance. this shift in market dynamics comes after a noteworthy slump, rendering it an intriguing development for investors and market watchers.

stock surge and comparison with cac 40

over the last 21 trading sessions, chausseria shares witnessed a remarkable 33% surge, advancing from eur5 to eur6.65. this development marked a return to growth after five consecutive sessions of losses. interestingly, chausseria's recent achievement goes hand in hand with france's benchmark stock market index, cac 40, which also registered gains over four consecutive sessions, reaching eur7,432.77, up by 0.65%.

return on equity and revenue

chausseria trades at a price-to-earnings ratio of 14.15, representing investors' willingness to pay eur14.15 for every euro of earnings produced annually. despite this notable increase in stock price, chausseria remains at a 16.888% discount to its 52-week high of eur8.00. alongside, it's pivotal to note that the company's return on equity stands at 4.29%, even though it has faced an 8.9% revenue drop year-on-year, plunging to eur2.53 million.

trade volume and moving averages

the recent trading session reported a slight anomaly, with chausseria's trade volume catapulting to 135, significantly surpassing its average daily volume of 26. the new trade volume exceeds both its 50-day moving average of eur5.16 and the 200-day moving average of eur5.20, suggesting a potential upswing for the stock.

future prospects and conclusion

given the evolving economic scenario and its ceaseless impact on global stock markets, chausseria's stock surge can be perceived as a sign of regained trust in the retail sectors or a simple repercussion of the broader market movements. regardless, if the company manages to extend its current upward trends, it may turn out to be a lucrative venture for its investors.

more news about chausseria (chsr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com